3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Brain Neoplasms
10
Breast Neoplasms
8
Carcinoma, Non-Small-Cell Lung
5
Neoplasms
4
Lung Neoplasms
3
Leukemia, Myeloid, Acute
3
Head and Neck Neoplasms
3
Central Nervous System Neoplasms
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Oligodendroglioma
2
Melanoma
2
Glioma
2
Glioblastoma
2
Ependymoma
2
Carcinoma, Renal Cell
2
Astrocytoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Triple Negative Breast Neoplasms
1
Thymus Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Salivary Gland Neoplasms
1
Interventions
Radiotherapy
9
Cisplatin
9
pembrolizumab
6
Methods
6
fludarabine
4
Papillomavirus Vaccines
4
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
4
Early Intervention, Educational
4
Cyclophosphamide
4
durvalumab
3
aldesleukin
3
Vaccines, Synthetic
3
Vaccines
3
Radiosurgery
3
Radiation
3
Platinum
3
Palliative Care
3
Paclitaxel
3
Nivolumab
3
Gemcitabine
3
Carboplatin
3
Brachytherapy
3
Bleomycin
3
1,2-diaminocyclohexaneplatinum II citrate
3
tremelimumab
2
lenvatinib
2
entinostat
2
aflibercept
2
Trastuzumab
2
Specimen Handling
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Vulvar Neoplasms
×
alovudine
×
Clear all
NCT01399658
2023-03-14
AMIGO
Dana-Farber Cancer Institute
Phase 2
Completed
93 enrolled
5 charts